← Back to Search

Monoclonal Antibodies

Atezolizumab for Non-Small Cell Lung Cancer

Phase 2
Waitlist Available
Led By Nasser Hanna, MD
Research Sponsored by Nasser Hanna
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Must have known PD-L1 status using the Dako 22C3 antibody (+ vs. -) OR must have at least 5 unstained slides to perform PD-L1 testing (results not required for eligibility). PD-L1 positive is defined as a tumor proportion score (TPS) ≥ 1%. PD-L1 negative is defined as a TPS <1%.
Written informed consent and HIPAA authorization for release of personal health information. NOTE: HIPAA authorization may be included in the informed consent or obtained separately.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from c1d1 up to a maximum of 28 months or until death
Awards & highlights

Study Summary

This trial is testing a new combination cancer treatment that includes the drugs carboplatin, pemetrexed, atezolizumab, and bevacizumab. The treatment will be given every three weeks for up to four cycles, and patients who don't respond to the treatment after four cycles will be able to continue receiving the treatment until their cancer progresses or they experience intolerable side effects.

Eligible Conditions
  • Non-Small Cell Lung Cancer

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from c1d1 until death or up to a maximum of 28 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and from c1d1 until death or up to a maximum of 28 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Progression Free Survival
Secondary outcome measures
Disease Control Rate
Number of Participants With Adverse Events
Overall Response Rate
+1 more

Side effects data

From 2019 Phase 3 trial • 1225 Patients • NCT02008227
27%
Fatigue
25%
Decreased appetite
24%
Cough
19%
Dyspnoea
19%
Asthenia
18%
Constipation
18%
Pyrexia
18%
Nausea
16%
Diarrhoea
13%
Arthralgia
12%
Vomiting
12%
Anaemia
11%
Back pain
11%
Musculoskeletal pain
11%
Rash
10%
Headache
9%
Oedema peripheral
9%
Weight decreased
9%
Chest pain
9%
Insomnia
9%
Pruritus
9%
Pain in extremity
8%
Dizziness
7%
Upper respiratory tract infection
7%
Aspartate aminotransferase increased
7%
Myalgia
7%
Haemoptysis
6%
Influenza like illness
6%
Nasopharyngitis
6%
Alanine aminotransferase increased
6%
Bronchitis
6%
Productive cough
5%
Musculoskeletal chest pain
5%
Depression
5%
Dry skin
4%
Abdominal pain
4%
Urinary tract infection
4%
Neuropathy peripheral
4%
Paraesthesia
3%
Stomatitis
3%
Dysgeusia
3%
Pneumonia
2%
Malaise
2%
Pleural effusion
2%
Neutropenia
1%
Lacrimation increased
1%
Respiratory tract infection
1%
Sepsis
1%
Pneumonitis
1%
Mucosal inflammation
1%
Bone pain
1%
Pulmonary embolism
1%
Peripheral sensory neuropathy
1%
Alopecia
100%
80%
60%
40%
20%
0%
Study treatment Arm
Atezolizumab
Docetaxel

Trial Design

1Treatment groups
Experimental Treatment
Group I: Carboplatin, Pemetrexed, Atezolizumab plus BevacizumabExperimental Treatment4 Interventions
Carboplatin (AUC 5) i.v. day 1 plus pemetrexed (500 mg/m2) i.v. day 1 plus atezolizumab 1200 mg i.v. day 1 plus bevacizumab 15 mg/kg i.v. day 1 every 3 weeks for up to 4 cycles. Patients with non-PD after 4 cycles will be permitted to continue with maintenance therapy with pemetrexed plus atezolizumab plus bevacizumab every 3 weeks until the time of disease progression or intolerable toxicities.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Pemetrexed
2014
Completed Phase 3
~5250
Atezolizumab
2016
Completed Phase 3
~6040
Bevacizumab
2013
Completed Phase 4
~5280
Carboplatin
2014
Completed Phase 3
~6670

Find a Location

Who is running the clinical trial?

Nasser HannaLead Sponsor
3 Previous Clinical Trials
120 Total Patients Enrolled
Genentech, Inc.Industry Sponsor
1,538 Previous Clinical Trials
567,650 Total Patients Enrolled
Nasser Hanna, MDPrincipal InvestigatorIndiana University School of Medicine
6 Previous Clinical Trials
393 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many participants have joined this experiment thus far?

"This medical trial has ceased recruitment as of February 16th 2022. At present, there are 1,371 clinical trials for carcinoma non-small cell lung and 1,284 studies with Atezolizumab actively seeking participants."

Answered by AI

What afflictions does Atezolizumab typically treat?

"Atezolizumab has been used to successfully treat endometrial cancer, melanoma and recurrent ovarian epithelial cancers that remain sensitive to platinum-based chemotherapy."

Answered by AI

Are there any vacancies for willing participants in this experiment?

"Currently, this clinical trial is not enrolling. Initially posted on November 15th 2018 and last edited on February 16th 2022, the study has been placed in a dormant state. If you are looking for other trials to participate in, there are 1,371 studies actively recruiting those with carcinoma non-small cell lung cancer and 1,284 studies seeking patients for atezolizumab treatment."

Answered by AI

How many medical centers in this state are administering the trial?

"Individuals interested in participating can register at University of Virginia Health System (Charlottesville, VA), ProHealth Care (Waukesha, WI) and the University of Wisconsin (Madison, IN). Additionally there are 4 other locations."

Answered by AI

What other research projects have been conducted with Atezolizumab?

"As of now, 1284 clinical studies are being conducted on Atezolizumab with 33% in Phase 3. While a majority of these trials occur in Shanghai, there is an expansive network of 72492 sites hosting research involving the drug."

Answered by AI

What potential risks of injury are associated with Atezolizumab use?

"Based on the evidence currently available, our team at Power assessed Atezolizumab's safety to be a 2. As this is only Phase 2 of clinical trials, there has been data indicating its security but none in regards to efficacy yet."

Answered by AI
~5 spots leftby Mar 2025